

Efficacy and safety evaluation of the peptide candidate CBT-001-839 for CAIX-targeted cancer diagnostic and therapeutic radiopharmaceuticals



ONCOLOGY	Candidate
Product Type	Peptide-Radionuclide Conjugate
Indication	Clear cell renal cell carcinoma (ccRCC)
Target	CAIX (Carbonic anhydrase IX)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Therapeutic : Peptide ligand → Binding to cell surface target protein → emission of Radiation(β-rays) → Death of cancer cells due to cell DNA damage (therapeutic) • Diagnostic: Peptide ligand → Binding to cell surface target protein → emission of radiation(γ-rays) -> PET/CT
Competitiveness	<ul style="list-style-type: none"> • Excellent PK Profile compared to competing molecules • Strongly bind to cancer and clears out rapidly to minimize toxicity • Stable and long-lasting binding
Development Stage	Candidate
Route of Administration	IV injection